Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: endocrine, other_emerging
- Who it enrolls
- age 18 Years to 40 Years; female; no BMI minimum stated; conditions: Polycystic Ovary Syndrome (PCOS); Obesity; Infertility, Female
- Interventions
- GLP-1 receptor agonist; Metformin
- Conditions
- Polycystic Ovary Syndrome (PCOS); Obesity; Infertility, Female
- Phase and size
- NA · 406 participants
- Dates
- Start 2026-07
Primary completion 2028-12 - Sponsor
- Peking University Third Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Ongoing Pregnancy RateFirst cycle of IVF/ICSI-ET (the first frozen-thawed embryo transfer cycle if all embryos are cryopreserved after oocyte retrieval)
02Eligibility
Who can take part
Inclusion Criteria: * Women with a wish to conceive; * Women with PCOS (Rotterdam criteria); * 28 kg/m2≤BMI\<35kg/m2; * Age: 18-40 years old Exclusion Criteria: * Women with diseases unsuitable for pregnancy or any other contraindications to infertility treatment Endocrine disorders; Abnormalities in liver and kidney function; Other medications such as glucocorticoids, anti-androgen drugs ;(spironolactone, cyproterone acetate, flutamide, etc.) within the last 3 months; Acute infections, severe cardiovascular disease, malignant tumors; Ongoing weight loss therapy (\>5% weight loss in the last 3 months) or history of gastrointestinal surgery; Uterine abnormalities that may affect assisted reproductive outcomes, untreated hydrosalpinx Male azoospermia, severe oligozoospermia and asthenospermia, or patients receiving donor sperm treatment Chromosomal abnormalities, patients planning preimplantation genetic testing (PGT) or donor oocyte treatment History of recurrent miscarriag Allergic to or contraindicated for GLP-1 class medications.
03Change log
Registry changes
No changes recorded since the trial was added.